Andreas Wollenberg
Andreas Wollenberg is an expert in Dermatology at University Hospital Augsburg (Germany). As of October 2026, ScienceLeadR ranks Andreas Wollenberg in the top 1% of experts worldwide for Dermatitis, Hypersensitivity and Sexually Transmitted Diseases. Andreas Wollenberg has authored 544 publications, the most recent in 2026, and is an investigator in 26 clinical trials, 4 of them ongoing. SLR score: 2,431 (community average: 125). How the SLR is computed.
LeadR Profile
Dermatology
Subspecialties: Immunology - Genetics - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
Prof. Dr. med. Dr. h.c. Andreas Wollenberg
University Hospital Augsburg, Augsburg, Germany
Andreas Wollenberg is a Professor of Dermatology and Allergy, working at the University Hospital Augsburg, Germany. In addition, he is teaching at the Ludwig-Maximilian University in Munich, Germany. Moreover, he is affiliated with the Comprehensive Center for Inflammatory Medicine at the University Hospital Lübeck, Germany. Prof. Wollenberg completed his internship and residency at Ludwig-Maximilian University in Munich and subsequently trained at The Scripps Research Institute in La Jolla, California, USA.
Prof. Andreas Wollenberg has conducted research in the field of atopic dermatitis, experimental dermatology, dendritic cell research, eczema herpeticum, perioral dermatitis and EGFR-inhibitor-induced skin toxicity. His research has generated more than 410 peer-reviewed publications and a Hirsch Index of 81. He has described and characterized the inflammatory dendritic epidermal cells, as well as the cutaneous plasmacytoid dendritic cells, and has coined the concept of proactive therapy.
Currently, he is a member of the editorial board of the Journal of the European Academy of Dermatology and Venerology, and a reviewer for many biomedical journals. Prof. Wollenberg has served for 10 years as head of the European Task Force on Atopic Dermatitis (ETFAD) and has authored the ETFAD Position Paper on AD management. Moreover, he is the lead author of the current EuroGuiDerm Guidelines for Atopic Dermatitis. Prof. Wollenberg is executive board member and Secretary of the International Society of Atopic Dermatitis (ISAD). He received a Dr. honoris causae from the Medical University Iuliu Hatieganu in Cluj-Napoca.
Organizations
Career arc: 1989 - 2026
Number : 544
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 26
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
4 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Phase 3 Study of Barzolvolimab in Participants with Cold Induced Urticaria and Symptomatic Dermographism 2025-522583-32-00 — urticaria, cold temperature, multiple chronic conditions, therapeutics | Phase 3 | Recruiting | 2026 |
| A Study to Evaluate the Long term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis 2024-519795-11-00 — safety, dermatitis, dermatitis, atopic | Phase 2 | Recruiting | 2025 |
| Intervention With Tralokinumab in Patients With Moderate to severe Atopic Dermatitis With Genital Impact NCT07444801 — microscopy, confocal, dermatitis, tomography, immunoglobulin a, microscopy, tomography, optical coherence, therapeutics, dermatitis, atopic | N/A | Recruiting | 2025 |
| A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate to Severe Atopic Dermatitis NCT06136741 — injections, gtp-binding proteins, safety, dermatitis, pharmaceutical preparations, solutions, rhoa gtp-binding protein, therapeutics, guanosine triphosphate, dermatitis, atopic | Phase 2 | Active not recruiting | 2023 |
LeadR Networks
Main global connection map